Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Assets: 2020-2024

Historic Other Non-Current Assets for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $1.7 million.

  • Foghorn Therapeutics' Other Non-Current Assets rose 17.10% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 17.10%. This contributed to the annual value of $1.7 million for FY2024, which is negligibly% changed negligibly from last year.
  • Per Foghorn Therapeutics' latest filing, its Other Non-Current Assets stood at $1.7 million for FY2024, which was down 0.00% from $1.7 million recorded in FY2023.
  • Over the past 5 years, Foghorn Therapeutics' Other Non-Current Assets peaked at $2.4 million during FY2021, and registered a low of $1.7 million during FY2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $1.7 million (2024), whereas its average is $1.9 million.
  • In the last 5 years, Foghorn Therapeutics' Other Non-Current Assets soared by 38.49% in 2021 and then dropped by 28.21% in 2023.
  • Foghorn Therapeutics' Other Non-Current Assets (Yearly) stood at $1.7 million in 2020, then surged by 38.49% to $2.4 million in 2021, then fell by 0.88% to $2.4 million in 2022, then declined by 28.21% to $1.7 million in 2023, then remained steady at $1.7 million in 2024.